NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
78.80 -1.00 (-1.25%) GOLD FUTURES
2,425.30 -13.20 (-0.54%) DOW
39,821.97 +15.20 (+0.04%) Bitcoin GBP
54,885.62 +1,240.16 (+2.31%)
Amgen Inc. (AMGD.XC)
| Previous close | 289.55 |
| Open | 288.70 |
| Bid | 284.40 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 288.70 - 288.70 |
| 52-week range | 210.60 - 304.00 |
| Volume | |
| Avg. volume | 2 |
| Market cap | 154.869B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 44.90 |
| EPS (TTM) | 6.43 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | 8.26 (2.85%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
BenzingaAmgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
PR NewswireNEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared
